Botulinum Toxin Market to Grow at a CAGR of 7.9% During 2024-2032; Surging Demand for Non-Invasive Cosmetic Procedures to Drive Market Growth

The global botulinum toxin market size was valued at USD 8.14 billion in 2023. The market is projected to grow from USD 8.74 billion in 2024 to USD 16.01 billion by 2032, exhibiting a CAGR of 7.9% during the forecast period.

Fortune Business Insights™ presents this information in its report titled, “Botulinum Toxin Market Size, Share & Industry Analysis, By Application (Therapeutic {Chronic Migraine, Spasticity, Overactive Bladder, Cervical Dystonia, Blepharospasm, and Others} and Aesthetics), By Type (Botulinum Toxin Type A and Botulinum Toxin Type B), By End-user (Specialty & Dermatology Clinics, Hospitals & Clinics, and Others), and Regional Forecast, 2024-2032”.

Botulinum is a neurotoxin produced by a gram-positive anaerobic bacterium known as clostridium botulinum. It can be further classified into seven different neurotoxins with serological and antigenic characteristics and sharing similar structures. The rising demand for non-invasive cosmetic procedures due to advanced product launches, reimbursement policies, and surging disposable incomes drives market expansion.

The market was negatively impacted by the COVID-19 pandemic, with decreased revenue from neurotoxin preparations witnessed by the key market players during the 2020 financial year.

Sue Ellen Cox, M.D. Announced Results of Phase 2 Study Evaluation Safety of 40U PrabotulinumtoxinA-xvfs

In October 2023, Evolus, Inc.’s Sue Ellen Cox M.D. announced the final results of the Phase 2 study for 40U PrabotulinumtoxinA-xvfs at the 2023 American Society for Dermatologic Surgery (ASDS) Annual Meeting in Chicago. The study was conducted to evaluate the safety, duration, and efficacy of the effects of 40U PrabotulinumtoxinA-xvfs.

Rising Demand for Invasive and Non-Invasive Procedures to Boost Market Growth

The surging demand for minimally invasive and non-invasive procedures is driving the botulinum toxin market growth. The sudden surge in the number of people seeking painless and simple ways to look healthy and young without dealing with the problems associated with invasive cosmetic procedures drives the demand for invasive and non-invasive procedures. The rising demand for these procedures also raised the concentration of manufacturers and suppliers on these products.

However, the increase in counterfeit products due to the high demand for botulinum toxin may impede market expansion.

Growing Key Players’ Focus on New Product Launches to Bolster Market Expansion

The market comprises key players, such as Ipsen Pharma, Medytox, and others. The growing focus of these key players is on adopting strategic initiatives, such as regulatory approvals and new product launches, to market their products globally to drive market growth.

Notable Industry Development

• August 2022: ATGC Co., Ltd. entered into a strategic partnership, license, and supply agreement with RELIFE S.r.l (Menarini Group) for ATGC-100 (Botulinum Toxin Type A, 900kDa), marking its strategic expansion into Europe and the U.K.

To get a detailed report summary and research scope of this market, click here:

https://www.fortunebusinessinsights.com/industry-reports/botulinum-toxin-market-100996

List of the Companies Profiled in the Report:

• AbbVie Inc. (U.S.)


• Ipsen Pharma (France)


• Merz Pharma (Germany)


• Medytox (South Korea)


• GALDERMA (Switzerland)


• Lanzhou Institute of Biological Products Co., Ltd. (China)


• HUGEL, Inc. (South Korea)


• Evolus, Inc. (U.S.)


• Revance Therapeutics, Inc. (U.S.)


• Supernus Pharmaceuticals, Inc. (U.S.)

Further Report Findings-

• North America was valued at USD 5.40 billion in 2023 and holds the largest botulinum toxin market share. The growth is attributed to the rising acceptance of these procedures among the people in North America.


• Europe witnessed the second-largest market share, with a rising number of people choosing these procedures in major markets across Europe.


• Asia Pacific is expected to grow at a faster CAGR during the forecast period. The rising popularity of Botulinum toxin procedures across the Asia Pacific is owing to the surge in chronic diseases and the increasing physical awareness in the region.


• The surging procedure volumes in key Latin American nations, including Brazil, are expected to drive market growth during the forecast period in Latin America.

Table of Segmentation: